Hester Biosciences Limited — Important, 30-01-2025: Financial Result Updates

**Consolidated Financials Overview**

For the quarter ended 31 December 2024, Hester Biosciences reported total income of ₹641.29 crore, a decrease of 14.3% year-over-year, with revenue from operations at ₹628.26 crore, marking a 4% decline compared to ₹655.05 crore in Q3 FY24. In contrast, total income for the nine months period reached ₹2,135.00 crore, up marginally from ₹2,153.42 crore, while revenue saw a slight decline overall in this period.

**Revenue Growth Analysis**

The 4% drop in quarterly revenue primarily stems from a 24% dip in the Animal Healthcare Division dragged by seasonal impacts and reduced milk prices affecting farmer spending. However, the Poultry Healthcare Division demonstrated resilience with a 12% increase in Q3 revenue, attributed to vaccine sales growth of 20%. The Petcare Division exhibited exceptional growth of 105% this quarter, highlighting Hester's commitment to expanding this new segment.

**Profit and EPS**

Net profit for Q3 declined sharply by 31% year-on-year to ₹44.39 crore, translating to an EPS of ₹5.22, down from ₹7.61. Over the nine-month period, profit after tax improved by 13%, reaching ₹222.07 crore, showcasing better operational resilience in a longer timeframe.

**Operational Cost Review**

Total expenses equaled ₹576.38 crore for the quarter, slightly mitigated by demand-driven cost efficiencies. Costs of materials and stock-in-trade decreased, offsetting higher employee benefits expenses which increased 1.5%. The overall operational cost discipline mirrors Hester's focused strategy on efficient management amidst fluctuating market dynamics.

**Balance Sheet & Cash Flow Insights**

As of the latest financials, total liabilities stood at ₹2,356.09 crore, slightly up from ₹2,373.95 crore a year ago, indicating stable leverage levels. Cash flows reflect sound management, with strategic investments in product expansion and consolidation of market positions evident in the balance sheet health.

**Strategic Position and Outlook**

Looking forward, Hester aims to drive revenue recovery by enhancing vaccination programs and launching alternative products in the Animal Healthcare segment to mitigate regulatory impacts. The potential launch of the Avian Influenza vaccine is anticipated to bolster future performance, particularly in the Poultry segment. The strong growth trajectory in Petcare suggests a meaningful diversification strategy that could yield positive results in the near term.

**Investor Insight**

Considering the recent financial metrics, a cautious approach is advisable. The solid long-term growth prospects combined with short-term revenue declines and profitability pressures suggest a 'hold' stance while monitoring the execution of strategic initiatives and market responses to product launches.